達實智能(002421.SZ)簽約1.08億元數據中心項目
格隆匯5月5日丨達實智能(002421.SZ)公佈,,公司近日與深圳伍毅網絡科技有限公司就深圳5G雲數據傳輸交互中心項目有關事項協商一致,正式簽署了項目合同,簽約地點為上海市,合同金額約1.08億元,佔公司2021年度經審計營業收入的3.42%。
粵港澳大灣區是“東數西算”工程的重要樞紐節點,公司已在深圳承接報合大數據中心、國能商貿雲計算中心、招商證券數據中心等多個大型數據中心項目,正逐漸積累數據中心領域項目經驗並將在細分行業內樹立品牌形象。
此次簽約印證了公司在數據中心領域的綜合競爭實力,也為公司進一步通過創新驅動升級數據中心領域綜合技術能力、深度滿足客户需求提供高質量服務提供新的契機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.